Evidence that Human Skin Microbiome Dysbiosis Promotes Atopic Dermatitis

Michael R. Williams¹ and Richard L. Gallo¹

Patients with atopic dermatitis are frequently colonized by *Staphylococcus aureus*. If *S. aureus* is present, then the subject tends to have more severe disease. However, it is unclear if *S. aureus* is a cause of atopic dermatitis or a consequence of the abnormal epithelial environment. In this issue of the *Journal of Investigative Dermatology*, Meylan et al. present evidence from a prospective clinical trial that shows *S. aureus* colonization precedes onset of atopic dermatitis in children. These observations suggest that *S. aureus* may cause atopic dermatitis in some individuals.

In this study, we observed a distinct increase of *S. aureus* prevalence at age 3 months in infants who later developed AD.

*S. aureus* colonization in longitudinal studies

Although multiple clinical studies had previously shown increased *S. aureus* colonization in children and adult patients with existing AD, it remains unclear if *S. aureus* precedes the onset of clinically apparent disease. To address this, large prospective longitudinal studies analyzing the microbiome from birth are needed. In 2017, Kennedy et al. described a study of 50 infants from birth to 2 years of age who were swabbed at four different skin sites at three time points in the first 6 months of life. Using 16S ribosomal RNA gene DNA sequencing, the researchers did not detect significant increases in *S. aureus* colonization on the 10 infants who developed AD, and they therefore concluded that *S. aureus* colonizes skin after onset of AD. However, a potential causal association of AD with the microbiome was seen with other non-identified members of the *Staphylococcus* genus, and their presence correlated with a better outcome of AD (Kennedy et al., 2017). Meylan et al. (2017) now present a larger longitudinal study of 149 infants who were sampled in the axillae and the antecubital fossae seven times during the first 2 years of life. AD developed in 36 of these subjects. This study was performed with higher-resolution, but lower-sensitivity, culture-based techniques for identification of bacterial species. This study detected *S. aureus* colonization before clinical onset of AD. Furthermore, another member of the *Staphylococcus* genus, *Staphylococcus hominis*, was observed to be statistically less abundant in AD and potentially protective (Meylan et al., 2017).

Recent experimental evidence that *S. aureus* can induce AD-like phenotypes

Experiments done in vitro and in mice suggest that *S. aureus* could promote disease through secretion of multiple virulence factors. Some of the most well-studied virulence factors include toxic shock syndrome toxin-1, enterotoxins, proteases (e.g., aureolysin, V8, and exfoliative toxins), and lysins (e.g., α-toxin and phenol-soluble modulins). It has been clearly shown that these factors can elicit both toxicity and/or inflammatory responses in skin cells that are directly exposed to microbes. Although in vitro studies of the effect of *S. aureus* on skin cells is important mechanistically, in vivo murine models of live *S. aureus* colonization have provided even stronger evidence that *S. aureus* colonization can induce AD skin phenotypes. We have shown that colonization of murine skin by *S. aureus* directly induces serine protease activity that disrupts the epidermal barrier (Williams et al., 2017) and that expression of T helper type 2 cytokines in the skin (a hallmark of the AD phenotype) is dependent on proteases secreted by *S. aureus* (Nakatsuji et al., 2016). Additionally, Nakamura et al. (2013) have observed that *S. aureus* delta toxin increases allergic responses and promotes both inflammation and
desquamation of the skin surface. Collectively, these and several other reports provide strong supporting mechanistic evidence that can explain how *S. aureus* colonization could promote AD in genetically susceptible individuals.

**Current therapeutic strategies to combat *S. aureus***

The etiologic role of *S. aureus* in AD suggested by the work discussed suggests that targeted elimination of *S. aureus* should be beneficial. Previously, methods including topical antimicrobials, systemic antibiotics, and bleach baths have been used alone or in different combinations to remove bacteria. Although these treatments are occasionally effective in treating AD, it has not been clear if the treatments eliminate *S. aureus* colonization. Furthermore, antibiotic treatments can also perturb the normal bacterial flora, and this can have a negative impact on potential benefits of the microbiome. In 2017, we described a potential method to specifically target *S. aureus* colonization on AD skin using a skin microbiome transplant (Nakatsuji et al., 2017). In this approach, we isolated *S. aureus*, *Staphylococcus aureus* superantigen, cytotoxins

**Cytotoxins Proteases Antimicrobials Antimetabolites Anti-inflammatory**

**Microbiome**

**S. aureus cytotoxins, proteases**

**S. aureus superantigens, cytotoxins**

**Filaggrin, Claudin**

**Skin resident cells**

**Barrier components Cytokines Antimicrobials Proteases/Anti-Proteases Neuropeptides**

**Bone marrow derived cells**

**Cytokines Antimicrobials Immunoglobulins Proteases/ Anti-Proteases Histamine Neuropeptides**

Figure 1. Cells that participate in skin health and disruption during atopic dermatitis. Interactions among the skin microbiome (bacteria, fungi, and viruses), resident cells in the skin (keratinocytes, fibroblasts, adipocytes, neural elements, and vasculature), and bone marrow-derived cells of the immune system (dendritic cells, lymphocytes, are granulocytes) are essential for homeostasis in healthy skin. Each box denotes some of the responsible molecules and functions for each of these three cellular systems. In atopic dermatitis, molecular or cellular defects in these systems are associated with disease (indicated in red). Disease may manifest from individual or a combination of defective functions. *S. aureus, Staphylococcus aureus.*

**REFERENCES**


*COMMENTARY*

By 2017, we described a potential method to specifically target *S. aureus* colonization on AD skin using a skin microbiome transplant (Nakatsuji et al., 2017). In this approach, we isolated *S. aureus,* *Staphylococcus aureus* superantigens, cytotoxins species that secrete lantibiotics with strong antimicrobial activity against *S. aureus.* The presence of these coagulase-negative *Staphylococcus* strains was strongly associated with protection against *S. aureus* in the normal population, and when an expanded culture of these beneficial bacteria was applied to the skin of AD subjects, this significantly reduced *S. aureus* colonization. Ongoing trials will determine if this approach can be successful for longer periods of time and if this can improve the phenotype of AD.

**Integrating a model and future directions**

Overall, the essential role that the microbiome plays in shaping the human immune system suggests that AD is a clinical phenotype that reflects imbalance between the functions of the epidermis, the resident microbiome, and circulating cells of the immune system. As seen in Figure 1, each element of this triad is required for normal immune homeostasis. AD probably is a clinical phenotype that can be driven by a defect in any of these elements, and one of the key drivers of disease can be colonization by an abnormal skin microbiome that includes *S. aureus.* Additional basic research is needed to help guide clinical trials to confirm the role of *S. aureus* in AD.

**CONFLICT OF INTEREST**

RLG is a consultant for Matrisys, and Sente, Inc. Matrisys has licensed IP from UCSD for microbiome therapy. MRW states no conflict of interest.